Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET
Company Participants
Peter Vozzo – Investor Relations-ICR Healthcare
Jack Khattar – Chief Executive Officer
Tim Dec – Chief Financial Officer
Conference Call Participants
Andrew Tsai – Jefferies
Stacy Ku – TD Cowen
Annabel Samimy – Stifel
David Amsellem – Piper Sandler
Kristen Kluska – Cantor Fitzgerald
Operator
Good afternoon, and welcome to Supernus Pharmaceuticals Fourth Quarter and Full Year 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session. Instructions will follow at that time. As a reminder, this conference call is being recorded.
I would now like to turn the conference over to Peter Vozzo of ICR Healthcare, Investor Relations representative of Supernus Pharmaceutical. You may now begin.
Peter Vozzo
Thank you, Jacinda. Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals’ fourth quarter and full year 2024 financial results conference call. Today, after the close of the market, the company issued a press release announcing these results. On the call with me today are Supernus’ Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Tim Dec. Today’s call is being made available via the Investor Relations section of the company’s website at ir.supernus.com.
During the course of this call, the management may make certain forward-looking statements regarding future events and the company’s future performance. These forward-looking statements reflect Supernus’ current perspective on existing trends and information. Any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including those noted in the Risk Factors section of the company’s latest SEC filings. Actual results may differ materially from those projected in these forward-looking statements. For the benefit of those of you who may be listening to the replay, this call is being held
#Supernus #Pharmaceuticals #SUPN #Earnings #Call #Transcript